

AUG. 17. 2004 8:54AM AVENTIS US PAT DEPT
TO: US USPTO GENERAL

RECEIVED
CENTRAL FAX CENTER

AUG 17 2004

NO. 6479 P. 1/17

OFFICIAL

**FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:
DEAV2001/0073 US NP

Applicants:
WEITHMANN, et al.

Serial No.
10/065, 994

Filing Date:
12/09/2002

Title of Invention:
PYRIDINE-2,4-DICARBOXYLIC ACID DIAMIDES AND PYRIMIDINE-4,6-DICARBOXYLIC ACID
DIAMIDES AND THE USE THEREOF FOR SELECTIVELY INHIBITING COLLAGENASES

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, at 703-872-9306, on

Date of Deposit August 17, 2004

Printed Name of Person Signing Certificate Paul Irvine

Signature

Total Number of Pages Sent: 17

Attorney: George G. Wang

Group Art Unit: 1624

Examiner: Habte, Kahsay

To:
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit
account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**

- | | |
|----------------------------------------------------------------|-------------------------------------------------------------------------|
| <input type="checkbox"/> Amendment, 37 CFR _____ | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input checked="" type="checkbox"/> Extension of Time Petition | <input checked="" type="checkbox"/> Other <u>Reply to Office Action</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input type="checkbox"/> Other _____ |
| <input type="checkbox"/> Maintenance Fee Transmittal | |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

AUG. 17. 2004 8:55AM

AVENTIS US PAT DEPT **RECEIVED**
CENTRAL FAX CENTER

NO. 6479 P. 2/17

OFFICIAL

¹
AUG 17 2004

DEAV2001/0073 US NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
WEITHMANN, et al.

Examiner: Habte, Kahsay

Application No.: **10/065,994**

Art Unit: 1624

Filed: **12/09/2002**

Title: **PYRIDINE-2,4-DICARBOXYLIC ACID DIAMIDES
AND PYRIMIDINE-4,6-DICARBOXYLIC ACID
DIAMIDES AND THE USE THEREOF FOR
SELECTIVELY INHIBITING COLLAGENASES**

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, at 703-872-9306 on

August 17, 2004
Date of Transmission

Signature 

AMENDMENT UNDER RULE 111

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

This paper is in response to the Office Action mailed April 23, 2004.

Amendments to the Claims are reflected in the listing of claims
beginning on page 2 of this paper.

Remarks begin on page 14 of this paper.